Loading...
You are viewing a DELETED record.
This record information is displayed for reference purpose only and should be not used.
This document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Bovela® Vaccine
EN
Bovela
No
-
Person:Dra Patrícia Schwarztechnician in charge representing,Avenida das Nações Unidas, 14171, 18º andar - Torre B - Vila Gertrudes. 04794-000.São Paulo, São Paulo
04794-000, BrazilPhone: 55 11 4949-4700,Fax: 55 11 4949-4700,Website: http://www.boehringer-ingelheim.com.br/,Related OrganizationBoheringer Ingelheim Química e Farmacêutica Ltda. ()Private sector (business and industry)Avenida das Nações Unidas, 14171, 18º andar - Torre B - Vila Gertrudes. 04794-000.São Paulo, São Paulo
04794-000, BrazilPhone: 55 11 4949-4700,Fax: 55 11 4949-4700,Website: http://www.boehringer-ingelheim.com.br/,
Bovela is a vaccine developed to immunize bovines against the disease caused by the bovine viral diarrhea virus (BVDV) types 1 and 2, including the vaccination of cows and calves, in order to protect the fetus against transplacental BVDV infection.
This virus is a single stranded positive-sense RNA pestivirus from the Flaviviridae family that replicates only in the cytoplasm. Its genetic material codes for the EMS and NPRO proteins, which in their native form inhibit the interferon dependent (IFN-gamma) immune response type Th1, therefore inhibiting the host immune response.
The absence of coding sequences for these viral genome proteins impairs the virus's ability to inhibit the production of interferon, therefore promoting the host immune system. The vaccine is adjuvant-free and targeted for the active immunization of pregnant cows and of animals after three months of age, in order to reduce the clinical symptoms of the disease, viremia and viral excretion.
EN
This virus is a single stranded positive-sense RNA pestivirus from the Flaviviridae family that replicates only in the cytoplasm. Its genetic material codes for the EMS and NPRO proteins, which in their native form inhibit the interferon dependent (IFN-gamma) immune response type Th1, therefore inhibiting the host immune response.
The absence of coding sequences for these viral genome proteins impairs the virus's ability to inhibit the production of interferon, therefore promoting the host immune system. The vaccine is adjuvant-free and targeted for the active immunization of pregnant cows and of animals after three months of age, in order to reduce the clinical symptoms of the disease, viremia and viral excretion.
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-110658-4 Organism Pestivirus A (BVDV-1)Viruses
-
BCH-ORGA-SCBD-110712-3 Organism Pestivirus B ( BVDV-2)Viruses
Parental strains of the two viral types were isolated from animals infected in Germany (KE9, BVDV-1) and the United States (NY-93 and BVDV-2).
EN
pXIKE-B-NdN and pKANE99C
EN
- Virus-mediated gene transfer
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-110714-1 Erns coding sequence | Pestivirus A (BVDV-1)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-110715-1 Npro coding sequence | Pestivirus A (BVDV-1)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
Briefly, modified BVDV-1 and BVDV-2 RNA were transcribed in vitro from complete clones of cDNA pXYKE-B-NdN (corresponding to the modified BVDV-2) and pKANE99C (corresponding to the modified BVDV-1). Later on, the BVDV strains were propagated in MDBK-B2 cells lineage and the viral RNA was extracted to establish the cDNA standard library and to its extension by polymerase (RT-PCR) chain reaction. The target living virus, modified and attenuated, were obtained by cDNA elaboration after in vitro transcription and RNA transfection of MDBK cells.
Sequencing of master virus seeds (MVS) to modified BVDVs were used to inoculation in MDBKB2 cells and, after 48 hours of incubation, the supernatant material was removed and cells were cleansed and lysed. Total RNA was extracted from cells, examined for integrity and later converted into cDNA for sequencing. Results of sequencing the established MVS confirmed the presence of introduced deletions in Npro and Erns. When compared, the MVS sequences and original isolated KE9 and NY93 showed the presence of just minor differences in nucleotides that were determined to have no influence over the attenuated phenotype.
PCR data obtained for MVS and WVS (MVS + 5) of strains in vaccines of modified BVDV have also confirmed the presence of the introduced Npro deletion. The in vitro data were also supported by PCR data obtained in BVDV (virus isolation method) positive samples which showed that the introduced Npro deletion remained stable for several in vitro passages. Jointly, the data show that BVDV genomes containing the inserted deletions are genetically stable in vitro and in vivo.
EN
Sequencing of master virus seeds (MVS) to modified BVDVs were used to inoculation in MDBKB2 cells and, after 48 hours of incubation, the supernatant material was removed and cells were cleansed and lysed. Total RNA was extracted from cells, examined for integrity and later converted into cDNA for sequencing. Results of sequencing the established MVS confirmed the presence of introduced deletions in Npro and Erns. When compared, the MVS sequences and original isolated KE9 and NY93 showed the presence of just minor differences in nucleotides that were determined to have no influence over the attenuated phenotype.
PCR data obtained for MVS and WVS (MVS + 5) of strains in vaccines of modified BVDV have also confirmed the presence of the introduced Npro deletion. The in vitro data were also supported by PCR data obtained in BVDV (virus isolation method) positive samples which showed that the introduced Npro deletion remained stable for several in vitro passages. Jointly, the data show that BVDV genomes containing the inserted deletions are genetically stable in vitro and in vivo.
EN
- Vaccine
EN
EN
Record type | Field | Record(s) | |||||
---|---|---|---|---|---|---|---|
|
|||||||
|